Anti-inflammatory

T cells attack a cancer cell
#Anti-inflammatory #Canada #GPCRs #Immuno-oncology

Kainova secures funding to develop GPCR-targeting therapies 

Biopharmaceutical company Kainova Therapeutics has secured $32 million CAD (US $24 million) to accelerate the development of immuno-oncology and inflammation therapies.  This financing round was led by Investissement Québec, with funds set to support Kainova’s advancement of GPCR-targeting therapies.  The company’s lead asset DT-7012, a Treg-depleting anti-CCR8 antibody, is currently progressing in an ongoing Phase I/II DOMISOL trial for… Read More

#Business & Investment #News

#Anti-inflammatory #Clinical trial #Immunology

Apogee Therapeutics announces positive data for I&I antibody 

Biotechnology company Apogee Therapeutics has announced positive Phase I data for its antibody APG333.  APG333, a novel half-life extended TSLP antibody, has been developed for inflammatory and immunology (I&I) markets. In the double-blind, placebo-controlled, first-in-human Phase I clinical trial, APG333 was well tolerated across all cohorts of… Read More

#News

#AI / data analytics / healthtech / informatics #Anti-inflammatory #Artificial intelligence (AI) #Cancer research #Covid-19 #EpicentRx #Immunology / Virology & Vaccines #Oncology #Polypharmacologic #Precision medicine #Protein binders #Therapeutic targets

New podcast on the significance of drug repurposing

This is the latest episode of the free DDW narrated podcast, titled “Why drug repurposing is so significant for drug discovery” which covers three written for Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: AI use in repurposing drugs for Covid-19 and RRx-001: Jack… Read More

#News

Researcher in a medical lab
#Anti-inflammatory #Assay development optimisation & technology #Human disease models #In vitro #In vivo

From in vitro to in vivo: Effective translation for anti-inflammatory treatments

John Unitt, Vice President, Immunology and Inflammation Drug Discovery, at Sygnature Discovery, explores the importance of an effective translational process for preclinical and clinical success. The global anti-inflammatory therapeutics market was estimated to be $98.26 billion in 2022 and is forecast to reach $146.14 billion by 2032, growing at a… Read More

#Exclusive Content

Monoclonal antibodies
#Anti-inflammatory #Financing #Lassen Therapeutics #Monoclonal antibodies #Ophthalmology

$85m fund supports monoclonal antibody for fibro-inflammatory disorders

Antibody therapeutics company Lassen Therapeutics has closed an oversubscribed $85 million Series B financing. The proceeds will fund a Phase II study in thyroid eye disease (TED) with the company’s monoclonal antibody LASN01 and the continued development of LASN500 for cancer. The clinical programme for LASN01 is focused primarily in… Read More

#Business & Investment #News

#Anti-inflammatory #Cancer research #EpicentRx #Oncology #Polypharmacologic #Precision medicine #Protein binders #Therapeutic targets

RRx-001: Jack of all trades, master of…many

Listen to this article on the DDW podcast: Bryan Oronsky, Chief Development Officer at EpicentRx, discusses how one drug sourced from the defense and aerospace industry, could have many potential disese targets. Introduction The term “dilettante”, at least in English, connotes a sloppy bungler, a smatterer, a second rater, unskilled and… Read More

#Exclusive Content

E coli bacteria
#Anti-inflammatory #Bacteria #Immune response #Immune system #Molecular Biology #mRNA #Preclinical investigations

Scientists use mRNA to reprogramme the immune system

University of Queensland researchers have identified a pathway in cells that could be used to reprogramme the body’s immune system to fight back against both chronic inflammatory and infectious diseases. Dr Kaustav Das Gupta and Professor Matt Sweet from UQ’s Institute for Molecular Bioscience discovered that a molecule… Read More

#News

Arsenic Trioxide
#Anti-inflammatory #Arsenic Trioxide #Autoimmune disease #Graft vs Host Disease #Phase II trial #Stem cell transplant #Transplant

Phase II success for autoimmune disease platform in GVHD

BioSenic’s arsenic trioxide (ATO) autoimmune disease platform has completed a successful Phase IIb trial in chronic Graft vs Host Disease (cGVHD) and is preparing to move to a Phase III trial.  The BioSenic autoimmune platform was created by Medsenic to target systemic autoimmune diseases using ATO as… Read More

#News